Does FEHB Cover GLP-1? 2026 Plan Rules + What to Do If You’re Denied

Does FEHB cover GLP-1 medications? Yes — every FEHB plan must cover at least one GLP-1 for weight loss in 2026 plus at least two oral anti-obesity medications. That’s an OPM mandate, not a plan choice. Now here’s the part nobody tells you up front: which GLP-1, what tier, what prior authorization paperwork, what cost-share, and even which weight-management program you have to be enrolled in to keep your prescription — all of that varies wildly by plan.

Some 2026 changes hit hard. Kaiser raised member coinsurance to 50% for GLP-1s. GEHA moved Wegovy and Saxenda to non-preferred on most plans, and Zepbound is non-formulary entirely on every GEHA plan (Formulary Exception path only). BCBS FEP places Wegovy at Tier 3 with PA on Standard and Basic, with Zepbound on the excluded list. MHBP now requires CVS Weight Management Program enrollment to get anti-obesity meds at all. FSBP requires four weigh-ins and four Teladoc app engagements every 30 days.

The short version: does FEHB cover GLP-1? Yes, by mandate. Will Wegovy or Zepbound be cheap or easy? Not always. Will paperwork be involved? Almost certainly. Is there a path forward if you’re denied? Three of them.

Jump to the Coverage Matrix ↓

At-a-glance: verified coverage examples for the most-asked drugs

What we actually verified for this page

We pulled coverage rules directly from primary documents, not summaries of summaries. Sources checked include:

• OPM Carrier Letter 2023-01 and the 2026 Open Season Highlights for the program-level mandate.
• BCBS FEP’s 2026 Abbreviated Formulary, Pharmacy FAQ, and medical policies 5.99.027, 5.99.029, and 5.99.030.
• GEHA’s December 2025 GLP-1 Pharmacy Coverage FAQ.
• Kaiser Permanente’s 2026 FEHB GLP-1 Requirements document.
• MHBP 2026 Consumer Option brochure.
• FSBP 2026 brochure and AFSPA’s EncircleRx update.
• CMS Medicare GLP-1 Bridge page and the April 21, 2026 BALANCE delay announcement.

Where we could not verify a specific cost-share number or PA criterion, we say so directly. We’d rather flag a gap than give you a confident answer that turns out to be wrong on your plan.

What every FEHB plan is legally required to cover

Every FEHB carrier must cover at least one FDA-approved GLP-1 prescribed for weight loss and at least two additional oral anti-obesity medications in 2026. This requirement comes from OPM Carrier Letter 2023-01 and is reaffirmed in OPM’s 2026 Open Season Highlights. It applies to BCBS FEP, GEHA, Kaiser, MHBP, FSBP, and every other FEHB and PSHB plan.

“At least one GLP-1” is the floor, not a guarantee that your specific drug is covered. A plan can satisfy the OPM mandate by covering generic liraglutide while putting Wegovy on a non-preferred tier, or by listing Saxenda as preferred while requiring a Formulary Exception for Zepbound. All of those compliance paths satisfy the rule. None of them tell you whether your prescription is covered without paperwork.

OPM doesn’t set the prior authorization criteria. Each carrier writes its own. That’s why BCBS FEP requires documented weight-management program participation plus a 5% weight-loss benchmark for renewal; Kaiser requires documented failure of other anti-obesity medications first; MHBP requires CVS Weight Management Program enrollment as a precondition; and FSBP requires four weigh-ins and four Teladoc app engagements every 30 days.

The 2027 OPM Call Letter pushes plans further toward structured obesity management. OPM is asking carriers to incorporate intensive behavioral therapy (IBT) — BMI screening, dietary assessment, and counseling — both before and during anti-obesity medication coverage. MHBP and FSBP are already there for 2026.

What FEHB plans CAN still restrict (within the mandate)

The 2026 FEHB GLP-1 Coverage Matrix

Pulled from each plan’s primary documents. Every row cites a source. Last verified: April 28, 2026.

Nationwide PPO and major FEHB options

HMO / regional examples

Plans dropping or in transition for 2026

Plans we did not independently verify

How to verify your specific plan in 5 minutes

The Coverage Matrix is the starting point. Here’s how to confirm whatyour plan actually covers right now — because formulary listings can have errors, and plans can update mid-year.

1. 1
   Find your exact plan option. “BCBS FEP” isn’t one plan; it’s three (Standard, Basic, Focus). Same for GEHA (High, Standard, HDHP, Elevate, Elevate Plus) and MHBP (Standard, Value, Consumer Option). Coverage and cost-share differ by option.
2. 2
   Pull your plan’s 2026 brochure. Every FEHB plan posts a brochure on opm.gov plan information. Section 2 (“Changes for 2026”) lists what’s new. Section 5(f) (“Prescription Drug Benefits”) spells out tiers, copays, coinsurance, deductibles, and program requirements.
3. 3
   Use your carrier’s drug-cost transparency tool. OPM required carriers to offer real-time benefit tools for 2026. Search the exact brand name (Wegovy, Zepbound, Saxenda). Note the tier, your copay or coinsurance after deductible, PA status, and any quantity limits.
4. 4
   Decode the symbols. PA = prior approval; ST = step therapy; QL = quantity limit; NC = not covered; Tier 1/2/3/4/5 = cost-share level.
5. 5
   Call the PBM. For BCBS FEP, GEHA, and MHBP, that’s CVS Caremark (1-844-443-4279 for GEHA’s GLP-1 questions). For Kaiser, it’s their integrated pharmacy. For FSBP, it’s Express Scripts. Ask: “Is [drug] covered under my [plan + option] for [weight loss / type 2 diabetes] in 2026? Is prior authorization required? Is there a weight management program requirement? What’s the estimated out-of-pocket cost? Can I get a call reference number?”
   The reference number matters. If you ever appeal, that call is documentation.

Plan-by-plan deep dives

What you’ll need for prior authorization (every plan)

Most FEHB plans gate GLP-1 weight-loss coverage through prior authorization, and the structure is consistent across plans. Four gates show up across BCBS FEP, GEHA, Kaiser, MHBP, FSBP, and most smaller carriers: a BMI threshold, a comorbidity or higher-BMI requirement, participation in a comprehensive weight-management program, and a 5% weight-loss benchmark for renewal. Document all four and your odds of approval are dramatically higher.

The four PA gates

1. 1. The BMI gate. Adults: BMI ≥ 30, OR BMI ≥ 27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, established cardiovascular disease). Pediatric patients (12–17): BMI at or above the 95th percentile for age.
2. 2. The lifestyle program gate. A documented comprehensive weight-management program — diet, exercise, behavioral modification. Teladoc (BCBS FEP, FSBP), CVS Weight Management Program (MHBP), Kaiser’s integrated lifestyle programs, in-person dietitian visits, and supervised group programs all qualify on the plans that accept them.
3. 3. The step therapy or trial gate (some plans). Kaiser explicitly requires documented intolerance or failure of other anti-obesity medications first. Your formulary symbols (“ST”) flag this on other plans.
4. 4. The renewal gate. ≥ 5% weight loss from baseline (or maintenance of initial 5% loss) within the first 3–6 months. Documented at BCBS FEP renewal and effectively at every other major plan.

What to bring to your PA appointment

• Current weight, height, and calculated BMI (recent — within the last 30 days)
• ICD-10 codes for any qualifying comorbidities (type 2 diabetes, hypertension, hyperlipidemia, OSA, established CVD)
• Documentation of any prior weight-loss medication trials (drug name, dates, outcomes)
• Documentation of structured weight-loss program participation (program name, dates, format, facilitator name)
• Recent lab work supporting comorbidities (A1C, lipid panel, blood pressure readings)

What “covered” actually costs you

Real out-of-pocket costs on FEHB GLP-1 coverage in 2026 range from a low Tier 1 copay on generic liraglutide on FEP, to several hundred dollars per month on a non-preferred tier or Kaiser’s 50% coinsurance, to full retail price if your plan denies you and you don’t pursue an alternative. The single biggest variable is your formulary tier. The single biggest unforced error is assuming “covered” automatically means “affordable.”

Type 2 diabetes coverage — Ozempic, Mounjaro, Rybelsus

Verified FEHB formulary examples list Ozempic, Mounjaro, and Rybelsus as covered type 2 diabetes medications, generally on lower formulary tiers than weight-loss-only GLP-1s. On BCBS FEP Standard and Basic 2026 formularies, Ozempic and Mounjaro are listed as covered diabetes drugs at Tier 2.

• Ozempic (semaglutide for T2D) sits on most major FEHB formularies as a covered T2D drug. Off-label use for weight loss commonly hits step therapy — plans want you to use Wegovy (the on-label weight-loss equivalent) first.
• Mounjaro (tirzepatide for T2D) is on most major FEHB formularies as a T2D drug. Off-label weight-loss use hits step therapy or denial in favor of the on-label equivalent (Zepbound).
• Rybelsus (oral semaglutide for T2D) is on FEHB formularies as a T2D drug for patients who can’t or won’t inject.

A note on diagnosis coding. If you don’t have type 2 diabetes, asking your doctor to code Ozempic as a T2D treatment isn’t a workaround — it’s a diagnosis-coding problem with real consequences. The on-label path for weight loss (Wegovy or Zepbound, or generic liraglutide) is almost always faster and your doctor’s office handles the coding correctly.

Cardiovascular risk reduction. Wegovy is FDA-approved to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight. This indication can sometimes unlock coverage on plans that are tighter on weight-loss-only use. Talk to your prescriber about whether your medical history qualifies.

Foundayo — what FEHB members should know about the new oral GLP-1

Foundayo (orforglipron) was FDA-approved on April 1, 2026 for adults with obesity, or some adults with overweight who also have weight-related medical problems, used alongside a reduced-calorie diet and increased physical activity. It’s a once-daily small-molecule oral GLP-1 that can be taken any time of day without food or water restrictions — a meaningful access difference from oral semaglutide.

FEHB coverage status for Foundayo. Plans are still updating formularies for 2026/2027. Per OPM’s standing requirement, FEHB carriers must annually evaluate their GLP-1 coverage as new drugs receive FDA approval. Check your plan’s pharmacy tool directly, and expect formulary placement to be in flux through the rest of 2026.

See also: Does insurance cover Foundayo? · Foundayo savings card

PSHB — postal workers

The Postal Service Health Benefits (PSHB) program — which replaced FEHB for most USPS employees and annuitants in 2025 — applies the same OPM mandate: every PSHB plan must cover at least one GLP-1 for weight loss. Coverage tiers and PA criteria mirror each carrier’s FEHB plan structure.

• PSHB is a parallel program under the same OPM oversight; rules on AOM coverage are the same.
• PSHB plan brochures are separate documents from FEHB brochures.
• 2026 PSHB enrollee premiums increased an average of 11.3%, slightly less than FEHB’s 12.3%.
• GEHA Elevate and GEHA Elevate Plus dropped from PSHB for 2026 (plan codes 58A–58F).
• The PSHB default plan for members who didn’t actively re-enroll in 2026 is FEP Blue Focus — important if your prior plan dropped.

Find your PSHB plan’s GLP-1 coverage at opm.gov/healthcare-insurance/pshb, locate your specific 2026 PSHB brochure, and read Section 5(f) for prescription drug benefits.

Annuitants and Medicare integration

FEHB annuitants and Medicare integration is plan-specific. FEHB-affiliated Employer Group Waiver Plans (EGWPs) and the FEP Medicare Prescription Drug Program (MPDP) can enhance Medicare Part D to retain coverage of GLP-1s for weight loss. Standard Medicare Part D is statutorily prohibited from covering weight-loss drugs. So the FEHB-EGWP integration is the structural protection — but only if you’re enrolled in the right FEHB option.

The Medicare GLP-1 Bridge

CMS launched the Medicare GLP-1 Bridge — a short-term demonstration running July 1, 2026 through December 31, 2027. The Bridge provides eligible Medicare Part D beneficiaries with coverage of Wegovy (injectable and tablet) and Zepbound for weight management at a $50 monthly copay (which does not count toward Part D out-of-pocket maximums). Eligibility: BMI ≥ 35 alone, or BMI ≥ 27 with clinical criteria.

The BALANCE Model status. CMS originally announced the BALANCE Model would launch in Medicare Part D January 1, 2027. On April 21, 2026, CMS delayed the Medicare Part D portion of BALANCE pending further evaluation. The Bridge was extended through December 31, 2027 to fill the gap.

Why this matters for FEHB annuitants: If your FEHB plan retains GLP-1 coverage through its EGWP, you’re already covered — you don’t need the Bridge. Don’t drop FEHB for Medicare Part D-only without understanding what you’d be giving up.

What to do if your FEHB plan denies your GLP-1

A denial letter is not the end of the road. You have a clear three-step escalation path: ask your prescriber to submit a reconsideration request with stronger documentation; pursue a Formulary Exception if the drug is non-formulary; and if still denied, file a disputed claim with OPM. Plan-level reconsideration with stronger documentation often addresses the most common denial reasons.

Common denial reasons and how to address each

When FDA-approved cash-pay makes more sense than fighting your FEHB plan

For some FEHB members — particularly those on plans with 50% coinsurance, those on non-preferred tiers, those whose drug is non-formulary, or those denied on appeal — FDA-approved cash-pay paths can be cheaper, faster, and less administrative than the insurance route. We’re not telling you to abandon insurance. We’re telling you to do the math on your specific situation.

When FDA-approved cash-pay actually wins:

• You have GEHA High/Standard/HDHP/Elevate Plus and your Wegovy moved to non-preferred (or Zepbound is non-formulary)
• You have Kaiser and 50% coinsurance is unworkable
• You’ve been denied on appeal
• You don’t expect to hit your annual OOP max
• You want a single-vendor experience without PA paperwork or pharmacy delays

Open Season strategy — choosing an FEHB plan for GLP-1 coverage

For 2026 — and looking forward to Open Season for plan year 2027 — the FEHB plans that give the most-aligned combination of GLP-1 coverage and cost-share, based on what we verified:

• BCBS FEP Standard or Basic — Generic liraglutide at Tier 1 with PA is the lowest-cost-share covered option satisfying the OPM mandate. Wegovy and Saxenda are Tier 3 with PA. Nationwide network. Strong PA infrastructure.
• GEHA Elevate — Only GEHA option that retained Wegovy and Saxenda as preferred for 2026. Zepbound still requires Formulary Exception.

Plans to scrutinize before relying on them

• GEHA High, Standard, HDHP, Elevate Plus — Non-preferred Wegovy/Saxenda; non-formulary Zepbound for 2026.
• Kaiser Permanente — 50% coinsurance on GLP-1s for 2026 (verify your specific Kaiser region).
• MHBP — Program enrollment required for AOMs; don’t skip enrollment.
• FSBP — EncircleRx four-weigh-in/four-engagement requirement is ongoing, not a one-time gate.

What to do during Open Season if GLP-1 coverage is your priority

1. Check the 2026 brochure for every plan you’re considering. Section 5(f) is prescription drug benefits; Section 2 is changes for the new plan year.
2. Use the carrier’s drug-cost transparency tool for your specific drug.
3. Call the carrier directly to confirm tier and PA criteria — formulary listings can have errors.
4. Consider total cost of care, not just GLP-1 cost-share. A slightly higher GLP-1 cost on a plan with much lower premium can net out cheaper.
5. Confirm the plan accepts the maximum government contribution (75% for some plans).

When the next Open Season is: For plan year 2027, Open Season is expected to run approximately mid-November through early December 2026 (verify exact OPM dates closer to the date). Coverage changes lock in until the next Open Season unless you experience a Qualifying Life Event.

Frequently asked questions

How we built and verified this page

We followed a strict source hierarchy:

1. OPM carrier letters and Open Season documents — for the program-level mandate.
2. Official FEHB plan brochures and formularies — for plan-specific coverage status.
3. Plan/PBM GLP-1 FAQs and medical policies — for tier placement and PA criteria.
4. FDA pages — for regulatory and approval status.
5. Provider official pages — for cash-pay program details and pricing.
6. Reddit and forum threads — used only to capture voice-of-customer language. Never used as coverage evidence.

Editorial recommendations are explicitly framed as editorial conclusions based on the verified facts above.